Kymera Therapeutics (KYMR) Misses Q4 EPS by 11c

Kymera Therapeutics (NASDAQ: KYMR) reported Q4 EPS of ($0.88), $0.11 worse than the analyst estimate of ($0.77). Revenue for the quarter came in at $7.39 million versus the consensus estimate of $14.71 million.

For earnings history and earnings-related data on Kymera Therapeutics (KYMR) click here.

You May Also Be Interested In

• Corning (GLW) files for up to $2B offering of common shares
• GMR Solutions to reprice $2.9B term loan, pay down $200M in debt
• Goldman, BofA vie to manage Anthropic employee wealth post-IPO - report